Drugs / Cingal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04231318 | Sep 2020 → May 2022 | osteoarthritis, knee | Anika Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Anika Therapeutics, Inc. | Results Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study anika.com ↗
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that Cingal® met its primary endpoint in a Phase III Study (Cingal 19-01), demonstrating superiority over triamcinolone hexacetonide (TH) steroid alone at 26 weeks post-treatment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-01 | Anika Therapeutics, Inc. | Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study anika.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cingal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04231318 ↗ |
| Route | Other | “Single intra-articular injection of Cingal into the knee.” NCT04231318 ↗ |